Financial Health Assessment: UTTERBERRY LTD

1. Financial Health Score: A-

Explanation: Utterberry Ltd exhibits exceptional financial strength and robust vital signs, akin to a peak-performance athlete. The company boasts a very strong asset base, excellent liquidity, and consistent growth in retained earnings. The only reason this falls short of an A+ is due to a significant, unexplained anomaly in the balance sheet (a sudden swelling of "other debtors") and a halving of the workforce, which require further diagnostic investigation to ensure there are no underlying complications.

2. Key Vital Signs (Current Period: Year Ending 30 June 2025)

• Liquidity (Blood Pressure): 19.2:1 Calculated as Current Assets (£9.85M) divided by Current Liabilities (£0.51M). A healthy ratio is typically between 1.5:1 and 2:1. Utterberry’s blood pressure is exceptionally high, meaning they have nearly £20 in short-term assets for every £1 of short-term debt. They are more than capable of meeting their immediate financial obligations.
• Solvency (Bone Density): Extremely Strong Net Assets (Shareholders' Funds) stand at £12.1M against Total Liabilities of £2.7M. The business is heavily equity-financed, meaning its structural foundation is incredibly solid and not overly reliant on external debt.
• Profitability Metabolism (P&L Reserve Growth): Robust Although the Profit & Loss account is not explicitly detailed (due to small company exemptions), the retained earnings surged from £8.23M to £11.13M—a growth of roughly £2.9M. This indicates a very healthy metabolism where the business is generating significant retained profit.
• Cash Reserves (Hydration Levels): Healthy Cash at bank increased from £726k to £1.08M. The company is well-hydrated and not suffering from the cash flow droughts that often plague growing enterprises.

3. Symptoms Analysis: What the Numbers Reveal

While the patient is in excellent overall health, a diagnostic review reveals a few notable symptoms that warrant attention:

• The "Other Debtors" Swelling (Anomaly): The most glaring symptom is the massive leap in "Other debtors" from £1.06M to £4.77M. While trade debtors (money owed by customers) actually decreased from £5.25M to £3.89M, this "other" category now makes up over half of all current assets. This could be a benign accumulation of R&D tax credits receivable, inter-company loans, or pre-payments, but a sudden four-fold increase is like a sudden lump—it requires a biopsy to rule out anything malignant, such as impaired or uncollectable related-party balances.
• Workforce Atrophy (Employee Reduction): The average number of employees dropped significantly from 18 to 8. For a company in the "research and experimental development on natural sciences and engineering" sector, human capital is the primary engine. Halving the workforce could be a symptom of successful automation, a strategic pivot, or, less optimistically, a cost-cutting measure following a loss of project funding.
• Long-Term Debt (Controlled Cholesterol): The company carries £2.7M in long-term bank loans, virtually unchanged from the prior year. Given the £3.88M in freehold property assets, this debt is well-secured and being serviced comfortably, acting more like good cholesterol supporting growth rather than bad cholesterol clogging the arteries.
• Director's Loan (Vitamin Supplement): The director (Mrs H Bevan, who owns over 75% of the shares) is owed £310,800, up from £249,394. This interest-free, repayable-on-demand loan acts as a vitamin supplement—showing the director's ongoing financial commitment and support for the business without draining external resources.

4. Diagnosis: Overall Financial Condition

Utterberry Ltd is a highly robust, asset-rich enterprise with a strong immunity to short-term economic shocks. The business has successfully transitioned from a smaller operation (net assets of £448k in 2016) to a substantial entity (net assets of £12.1M in 2025).

The core diagnosis is Financial Robustness with a Localized Anomaly. The balance sheet is heavily skewed towards fixed assets (freehold property) and debtors, meaning the company is wealthy on paper but must ensure its "other debtors" can be converted into cash. The reduction in staff numbers alongside massive profit retention suggests the company may have shifted from a labor-intensive R&D phase to a more streamlined operational or licensing phase, or it has successfully outsourced certain functions.

5. Prognosis: Future Financial Outlook

The prognosis is highly favorable. With nearly £1.1M in the bank, minimal short-term liabilities, and a multi-million-pound property asset base, Utterberry Ltd is well-insulated against future financial illness. The main risk to this positive outlook would be if the £4.77M in "other debtors" proves to be impaired. Assuming these balances are recoverable, the company has the financial muscle to weather market uncertainties and self-fund future R&D initiatives.

6. Recommendations: Prescriptions for Financial Wellness

1. Biopsy the "Other Debtors": Conduct an immediate review of the £4.77M in other debtors. Ensure this amount is fully collectable, properly secured, and adequately provisioned for if there is any doubt regarding recovery.
2. Cash Flow Circulation Check: While holding £1M in cash is healthy, having over £8.6M tied up in total debtors slows down cash circulation. Look at tightening credit control on the remaining trade debtors to convert more of that balance into liquid cash.
3. Review the Long-Term Debt Terms: With such strong cash generation and asset backing, it may be worth reviewing the terms of the £2.7M long-term loan. The company may be in a position to renegotiate for a lower interest rate or restructure the debt to improve financial efficiency.
4. Workforce Strategy Alignment: Ensure that the reduction in headcount (from 18 to 8) aligns with long-term strategic goals. In the R&D sector, losing key intellectual capital can harm future revenue streams. Verify that the remaining team has the capacity to deliver on the company's objectives.